Skip to content

Analysis of Treatment Progression in Atopic Dermatitis During Routine Care: Implementation of 3D Imaging and Automated Score Calculation Considering Environmental and Sociodemographic Factors

Analysis of Treatment Progression in Atopic Dermatitis During Routine Care: Implementation of 3D Imaging and Automated Score Calculation Considering Environmental and Sociodemographic Factors - AD_Autoscore

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00038226
Enrollment
100
Registered
2025-10-22
Start date
2025-07-29
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L20

Interventions

Group 1: Routine treatment of atopic dermatitis at the Department and Outpatient Clinic of Dermatology and Allergology with documentation at six visits every three months: a) Completion of a short med

Sponsors

Almirall S.A.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed atopic dermatitis with systemic treatment at the Department and Outpatient Clinic of Dermatology and Allergology. Information and written informed consent to voluntarily participate in the study.

Exclusion criteria

Exclusion criteria: Language barriers

Design outcomes

Primary

MeasureTime frame
Which types of treatment trajectories can be identified in atopic dermatitis in relation to individual influencing factors? Can standardized 3D whole-body imaging contribute to the assessment of disease severity and treatment progression in atopic dermatitis? Which environmental, psychological, demographic, and other factors influence the severity of atopic dermatitis and the patients’ quality of life during the course of treatment? Can future predictive markers for treatment progression be identified retrospectively? Which factors influence the course of treatment in atopic dermatitis? What is the relationship between the highest recorded peak disease value (e.g., Peak EASI) used to determine disease severity in atopic dermatitis and the subsequent therapy and treatment concept?

Countries

Germany

Contacts

Public ContactAlexander Zink

Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein

alexander.zink@tum.de+498941403176

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026